GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT NON PROFIT ORGANISATION

Their core work

TB Alliance is a US-based nonprofit dedicated to accelerating the discovery and development of new tuberculosis drug regimens. They bring deep expertise in TB drug pipeline management — from preclinical development through clinical trials — and contribute to large European consortia focused on designing faster, smarter ways to test TB treatments. Their work spans microbiology, clinical pharmacology, and innovative trial design, positioning them as a key bridge between TB drug discovery and patient access.

What they specialise in

How they've shifted over time

TB Alliance entered H2020 in 2019 with a broader clinical trial methodology focus — EU-PEARL addressed multiple diseases (depression, NASH, neurofibromatosis) alongside TB through a shared patient-centric trial platform. By 2020-2021, their involvement narrowed sharply to TB-specific work: ERA4TB tackled preclinical drug pipelines and UNITE4TB brought AI into TB clinical trials. The shift shows a move from general trial platform innovation toward deep, end-to-end TB drug development with increasingly computational methods.

TB Alliance is moving toward AI-augmented, end-to-end TB drug development — from preclinical candidates through innovative clinical trials — making them increasingly valuable for computational drug development partnerships.

How they like to work

TB Alliance operates exclusively as a consortium participant, never as coordinator, which reflects their role as a specialized domain contributor rather than a project manager. With 96 unique partners across 19 countries from just 3 projects, they work in very large consortia (averaging 30+ partners per project). This suggests they are a trusted specialist that major European health consortia actively seek out for TB-specific expertise.

Despite being US-based, TB Alliance has built a remarkably wide European network — 96 unique partners across 19 countries from only 3 projects. This breadth comes from participating in large-scale IMI-style health consortia that unite academia, pharma, and nonprofits.

What sets them apart

TB Alliance is one of very few US-based nonprofits participating in H2020 health consortia, bringing a global TB drug development perspective that most European partners lack. Their unique value is combining decades of TB-specific drug pipeline knowledge with willingness to contribute to shared European trial infrastructure. For any consortium tackling infectious disease drug development or clinical trial innovation, they offer unmatched TB domain credibility.

Highlights from their portfolio

• UNITE4TB
  Their largest funded project (EUR 1.4M), running until 2028, combining AI with innovative clinical trial design specifically for TB drug regimens.
• EU-PEARL
  A cross-disease clinical trial platform covering TB, depression, NASH, and neurofibromatosis — showing TB Alliance's ability to contribute beyond their core disease area.
• ERA4TB
  Targets the full preclinical-to-regimen pipeline for pan-TB treatment, running until 2026, addressing drug-resistant TB strains.